Lepton Global Solutions Announces Partnership with Satcube to Expand its Network Offering for Small, Portable VSATs
9.3.2021 17:00:00 EET | Business Wire | Press release
Lepton Global Solutions (www.leptonglobal.com), a Kymeta company, and leading provider of satellite-based customized turn-key communications solutions and services, announced today a strategic partnership with Satcube (www.satcube.com). The partnership will add Satcube’s class of extremely small VSAT terminals to the company’s global satellite network, which is engineered to support terminal aperture sizes down to 45cm. In turn, Lepton Global Solutions will offer Satcube Ku terminals globally as a comms-on-the-pause (COTP) solution that are complementary with the Kymeta™ u8 comms-on-the-move (COTM) offering, running both on the same frequencies with easily transportable and operated hardware.
Together, Lepton Global Solutions and Satcube are challenging the traditional ways satellite communications are delivered and consumed through highly automated, easily transportable products low in size, weight, and power. The goal of the partnership is to deliver world-class technology and services to defense, public safety, and commercial customers globally. Both the Satcube and the u8 terminal are designed to fulfill tactical, easy-to-use operational requirements. Their differing form factors and capability sets address differing applications of users on the move.
“Most commercial satellite service networks are designed for larger aperture antennas that operate at broadside, which means that smaller, flat panel terminals like the Satcube and u8 are not globally supported,” said Isabel LeBoutillier, Vice President of Kymeta Connect and Government Programs. “Our network has been built from the ground up to accommodate the technical requirements of this newer class of extremely small, flat-panel VSAT terminals. The partnership with Satcube will allow us to deliver superior connectivity options for more applications to our mobile customers.”
“This partnership will allow our companies to better meet the requirements of our complementary customers and provide solutions that fit the needs of a broader audience,” said Jakob Kallmer, Satcube CEO and founder. “Our relationship with Lepton will enable Satcube to provide a more seamless and reliable connectivity experience to our customers globally, and we couldn’t be more thrilled to be working together.”
Satcube Ku is an all-in-one compact carry-on satellite terminal with a flat antenna the size of a large laptop. The terminal enables users to create an easy-to-use Wi-Fi hotspot and receive high-speed broadband connection in less than one minute to execute critical, on the spot work assignments and communications.
Lepton Global Solutions and Satcube leverage Kymeta Broadband, which is the first satellite service designed to serve the unique characteristics of flat panel antennas used in land-mobile applications. Built from the ground up and software defined for disadvantaged terminals and antennas, the service ensures that customers stay connected without latency or throughput challenges. Customers receive capacity through a managed network that aggregates multiple satellite providers and hundreds of operators for global coverage.
Lepton’s network offering for these terminals includes global customized CIR plans as well as Kymeta Broadband’s satellite 5x2 MIR and hybrid satellite-cellular options. Service may be purchased for individual terminals or shared among multiple terminals.
About Lepton Global Solutions:
Lepton Global Solutions, a Kymeta company, specializes in the engineering and delivery of customized, yet cost-effective, turnkey satellite communications solutions to commercial and government customers. Lepton’s end-to-end solutions, which go beyond managed satellite services to include VSAT equipment installation, 24×7 technical support and customized back end IT infrastructure, are tailored to meet customer-specific needs.
Lepton is headquartered outside of Washington, D.C. in Tysons Corner, Virginia.
For additional information, please visit www.leptonglobal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005025/en/
Contact information
Business Inquiries for Lepton Global Solutions:
Jon Maron
Vice President of Marketing and Communications
Lepton Global Solutions
+1 425.658.8827
jmaron@kymetacorp.com
Media Inquiries for Lepton Global Solutions:
Amanda Barry
Associated Director PR
The Summit Group
abarry@summitslc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom